Prosecution Insights
Last updated: October 02, 2026

Examiner: LIN, JERRY

Tech Center 1600 • Art Units: 1631 1671 1684 1685

This examiner grants 72% of resolved cases

Analysis

Jerry Lin is an examiner in Tech Center 1600, Art Unit 1631, with a record of 840 resolved cases. The examiner's allowance rate is 72.3 percent, suggesting the probability of success for applications in this technology area. This 72.3 percent rate indicates the frequency of grants across the 840 cases handled, showing a tendency toward allowing applications that meet the necessary requirements.

The interview lift for this examiner is 14.7 percent. This lift represents a positive impact on the 72.3 percent base allowance rate. The 14.7 percent increase suggests that while the examiner allows a majority of cases, an interview can provide an additional boost to resolve remaining issues in the 840 cases handled. Practitioners should consider the 14.7 percent lift when planning their response to office actions.

The median days to allowance is 1427 days. This timeline indicates the prosecution period for the applications that eventually reach allowance. Practitioners should note that while the 72.3 percent allowance rate is a primary metric, the 1427-day median suggests that the process involves several stages of review. The data from 840 resolved cases provides a level of confidence in these performance metrics for Art Unit 1631.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

72.3%
Allow Rate
+12.3% vs TC avg
858
Total Applications
+14.7%
Interview Lift
1427
Avg Prosecution Days
Based on 840 resolved cases, 2023–2026

Rejection Statute Breakdown

33.3%
§101 Eligibility
14.4%
§102 Novelty
20.6%
§103 Obviousness
20.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18185105 VALIDATION OF INFERRED ANTICANCER PATHWAYS Non-Final OA Nant Holdings IP, LLC
17932712 SYSTEMS AND METHODS FOR IDENTIFYING SOMATIC MUTATIONS Final Rejection LIFE TECHNOLOGIES CORPORATION
17767615 Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples Final Rejection ImmunityBio, Inc.
18266111 Computational Method and System for Compression of Genetic Information Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18314780 ADJUSTMENT OF TOOTH POSITION IN A VIRTUAL DENTAL MODEL Non-Final OA Align Technology, Inc.
18215789 METHODS AND SYSTEMS FOR GENERATING REGULATORY ELEMENTS Non-Final OA MONSANTO TECHNOLOGY LLC
18452463 Methods and Systems for Analyzing Nucleic Acid Molecules Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18212949 METHODS OF TREATING CANCER Non-Final OA Vanderbilt University
18265479 METHOD AND SYSTEM FOR SIMULTANEOUS INTERPRETATION OF TAXONOMIC DISTRIBUTION AND REPLICATION RATES OF MICROBIAL COMMUNITIES Non-Final OA Tata Consultancy Services Limited
18464035 MULTIPLE-TIERED SCREENING AND SECOND ANALYSIS Non-Final OA Flagship Pioneering Innovations VI, LLC
17665849 DISTINGUISHING METHYLATION LEVELS IN COMPLEX BIOLOGICAL SAMPLES Final Rejection Illumina, Inc.
17996372 IMAGE GENERATION DEVICE, DISPLAY DEVICE, DATA CONVERSION DEVICE, IMAGE GENERATION METHOD, PRESENTATION METHOD, DATA CONVERSION METHOD, AND PROGRAM Non-Final OA Kewpie Corporation
18459747 Methods and Processes for Non-Invasive Assessment of Genetic Variations Non-Final OA SEQUENOM, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month